289 related articles for article (PubMed ID: 38391024)
1. HER2
Hu HH; Wang SQ; Zhao H; Chen ZS; Shi X; Chen XB
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38391024
[TBL] [Abstract][Full Text] [Related]
2. HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies.
Pous A; Notario L; Hierro C; Layos L; Bugés C
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511163
[TBL] [Abstract][Full Text] [Related]
3. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
[TBL] [Abstract][Full Text] [Related]
4. Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer.
Korsak B; Almeida GM; Rocha S; Pereira C; Mendes N; Osório H; Pereira PMR; Rodrigues JMM; Schneider RJ; Sarmento B; Tomé JPC; Oliveira C
Int J Cancer; 2017 Oct; 141(7):1478-1489. PubMed ID: 28639285
[TBL] [Abstract][Full Text] [Related]
5. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives.
Palle J; Rochand A; Pernot S; Gallois C; Taïeb J; Zaanan A
Drugs; 2020 Mar; 80(4):401-415. PubMed ID: 32077003
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective.
Aoki M; Iwasa S; Boku N
Gastric Cancer; 2021 May; 24(3):567-576. PubMed ID: 33646464
[TBL] [Abstract][Full Text] [Related]
7. Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.
Takahashi N; Furuta K; Taniguchi H; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y; Yamada Y
Oncotarget; 2016 Jan; 7(4):4925-38. PubMed ID: 26716644
[TBL] [Abstract][Full Text] [Related]
8. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
[TBL] [Abstract][Full Text] [Related]
9. HER2-positive gastric cancer.
Boku N
Gastric Cancer; 2014 Jan; 17(1):1-12. PubMed ID: 23563986
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.
Shao X; Zhan S; Quan Q; Shen Y; Chen S; Zhang X; Li R; Liu M; Cao L
Int Immunopharmacol; 2022 Sep; 110():108988. PubMed ID: 35777267
[TBL] [Abstract][Full Text] [Related]
11. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
[TBL] [Abstract][Full Text] [Related]
12. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis.
Wang HB; Liao XF; Zhang J
Medicine (Baltimore); 2017 Nov; 96(44):e8437. PubMed ID: 29095284
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
Cui Y; Li SB; Peng XC; Wu J; Fu GH
Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505
[TBL] [Abstract][Full Text] [Related]
15. Current status and future perspectives in HER2 positive advanced gastric cancer.
Roviello G; Catalano M; Iannone LF; Marano L; Brugia M; Rossi G; Aprile G; Antonuzzo L
Clin Transl Oncol; 2022 Jun; 24(6):981-996. PubMed ID: 35091998
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment.
Shitara K; Yatabe Y; Matsuo K; Sugano M; Kondo C; Takahari D; Ura T; Tajika M; Ito S; Muro K
Gastric Cancer; 2013 Apr; 16(2):261-7. PubMed ID: 22797858
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis.
Okita A; Imai H; Takahashi M; Takahashi H; Umegaki S; Kawamura Y; Hiraide S; Ouchi K; Sato Y; Okada Y; Komine K; Saijo K; Takahashi S; Takahashi M; Shirota H; Ohori H; Gamoh M; Ishioka C
Tohoku J Exp Med; 2018 Jun; 245(2):123-129. PubMed ID: 29937450
[TBL] [Abstract][Full Text] [Related]
18. [Predictive diagnosis of HER2 in gastric adenocarcinoma].
Daum O; Skálová A; Rozkos T; Laco J
Cesk Patol; 2011 Oct; 47(4):160-3. PubMed ID: 22145214
[TBL] [Abstract][Full Text] [Related]
19. Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
Mishima Y; Matsusaka S; Chin K; Mikuniya M; Minowa S; Takayama T; Shibata H; Kuniyoshi R; Ogura M; Terui Y; Mizunuma N; Hatake K
Target Oncol; 2017 Jun; 12(3):341-351. PubMed ID: 28508152
[TBL] [Abstract][Full Text] [Related]
20. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
